Navigate Reputation, Transparency, & Risk in Periods of Uncertainty

Session details:

Pharma and biotech operate in an environment where a single trial result, funding round, restructuring, or regulatory turn can shift sentiment overnight. As companies face portfolio reprioritizations, workforce reductions, investor scrutiny, and accelerated misinformation cycles, communications has become the frontline defense for maintaining trust. This panel explores how leaders protect corporate reputation, foster transparency during difficult transitions, and stabilize the narrative when headlines, analysts, or online discourse turn negative.